Overview

Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)

Status:
Completed
Trial end date:
2018-06-11
Target enrollment:
Participant gender:
Summary
The purpose of this crossover trial is to investigate whether atomoxetine (versus placebo) improves memory function in persons with memory deficits due to multiple sclerosis.
Phase:
Phase 2
Details
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Treatments:
Atomoxetine Hydrochloride